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The clinical epidemiology and course of the spectrum of renal
diseases associated with HIV infection.
Background. While an understanding of the epidemiology
and clinical course of HIV-associated nephropathy (HIVAN) is
growing, little is known about the risk factors and clinical course
of the other renal diseases that may also occur as a complica-
tion of HIV infection. This study was undertaken to compare
HIVAN to the spectrum of other kidney diseases seen among
HIV-infected patients.
Methods. This retrospective cohort study included all HIV-
infected patients who underwent renal biopsy during the course
of their clinical care at six major medical centers. Demographic
and clinical information were abstracted from each patient’s
clinical record. Time to initiation of renal replacement ther-
apy was compared for patients with lesions other than HIVAN
to patients with HIVAN using Cox proportional hazards
regression.
Results. Eighty-nine patients (47 with lesions other than
HIVAN and 42 with HIVAN) were available for inclusion. Pa-
tients with lesions other than HIVAN were less likely to be
black (37/47 vs. 42/42, P = 0.02), more likely to have a posi-
tive hepatitis B surface antigen (10/37 vs. 4/42, P = 0.04), less
likely to have the diagnosis of hypertension (24/46 vs. 31/42, P =
0.03), more likely to have a greater creatinine clearance at time
of biopsy (60.6 vs. 39.0 cc/min, P = 0.008), and have a greater
CD4 lymphocyte count at time of biopsy (287 vs. 187 cells/mL,
P = 0.04) compared to patients with HIVAN. Lesions other than
HIVAN were associated with a longer time to initiation of renal
replacement therapy compared with HIVAN (HR 0.33, 95% CI
0.15-0.71, P = 0.005). Other factors associated with a longer time
to renal replacement therapy included higher creatinine clear-
ance at time of biopsy, greater CD4+ lymphocyte count, the
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absence of hepatitis C antibody, and the use of an angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker.
The type of renal disease (HIVAN vs. other) interacted sig-
nificantly with HIV-1 RNA level and the use of antiretroviral
therapy (P = 0.0001 and 0.006, respectively). Among patients
with lesions other than HIVAN, the presence of nondetectable
HIV-1 RNA was not associated with a greater risk of progres-
sion of renal disease (HR 0.27, P = 0.24). Among patients with
HIVAN, because all patients had detectable virus at the time
of institution of renal replacement therapy, this highly signifi-
cant association could not be quantified. Among patients with
lesions other than HIVAN, the use of antiretroviral therapy was
not associated with the progression to renal replacement ther-
apy (HR 3.29, P = 0.06). Among patients with HIVAN, the use
of antiretroviral therapy was associated with a slower progres-
sion to renal replacement therapy (HR 0.24, P = 0.03).
Conclusion. Among HIV-infected patients with renal disease
other than HIVAN, viral suppression and the use of antiretro-
viral therapy are not associated with a beneficial effect on renal
function; thus, additional therapeutic strategies may need to be
utilized. Because renal histology is associated with prognostic
differences, these data provide outcomes information that will
improve the clinical utility of renal biopsy among HIV-infected
patients with renal disease.
HIV-related renal diseases are the third leading cause
of end-stage renal disease (ESRD) among African Amer-
icans aged 20 to 64 years [1]. While the most common
histologic lesion seen among HIV-infected patients with
renal disease is HIV-associated nephropathy (HIVAN), a
glomerulopathy demonstrating focal segmental glomeru-
losclerosis with collapsing features, a spectrum of other
histologic lesions occurs with almost an equal cumula-
tive frequency [2]. These lesions include amyloidosis,
minimal change disease, cryoglobulinemia, and various
forms of immune-complex glomerulonephritis, such
as IgA nephropathy, membranous nephropathy, and
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membranoproliferative glomerulonephritis [2–18].
While an understanding of the epidemiology and clinical
course of HIVAN is growing, little is known about the
risk factors and clinical course of the other renal diseases
that may also occur as a complication of HIV infection.
Based on estimates that renal histologies other than
HIVAN may account for between one third and one half
of the cases of renal disease among HIV-infected patients
[2, 18], an understanding of their risk factors and clinical
course is imperative to further investigation into preven-
tion and treatment strategies. This study was therefore
undertaken to establish a better understanding of the
clinical epidemiology and course of the spectrum of renal
diseases that complicates HIV infection. The risk factors,
clinical course, and potential modifying factors, including
CD4+ count, HIV-1 RNA level, and the use of antiretro-
viral medications will therefore be examined among
the spectrum of renal diseases that complicates HIV
infection.
METHODS
The retrospective cohort study included all HIV-
infected patients who underwent renal biopsy during
the course of their clinical care as determined by their
treating nephrologists at Indiana University School of
Medicine, Mount Sinai School of Medicine, Wake For-
est University, Emory University, MetroHealth Medi-
cal Center (Cleveland), and Duke University Medical
Center between January 1, 1995 and January 1, 2001. This
study was approved by the Institutional Review Board of
each institution. Because of the study design and meth-
ods, the Institutional Review Board at each institution
waived the requirement for consent. Therefore, no pa-
tient was contacted, all information was abstracted di-
rectly from the medical record, and data were collected
without the ability to subsequently link it back to the
individual.
Data collection
Demographic and clinical information at baseline were
abstracted for each patient from their clinical record to in-
clude gender, age, race, risk behavior for HIV acquisition,
hepatitis C antibody status, hepatitis B surface antigen
status, and the presence of either diabetes mellitus or hy-
pertension. Risk behavior for HIV acquisition was coded
as related to sexual activity versus intravenous drug use
(IVDU) among those patients in whom the information
was available. Diabetes mellitus was defined as the pres-
ence of glucose intolerance requiring dietary or pharma-
cologic management. Hypertension was defined by the
use of antihypertensive medications at the time of renal
biopsy.
Information reflecting the clinical course of each pa-
tient’s renal disease was also abstracted from the medical
record for each available clinical encounter from the time
of renal biopsy until the last available clinical encounter.
This information included weight, blood pressure, lab-
oratory studies of serum creatinine, CD4+ lymphocyte
count, HIV-1 RNA level, and the presence of proteinuria,
and medication use of antiretroviral therapy, prednisone,
angiotensin-converting enzyme inhibitors (ACEI), and
angiotensin receptor blockers (ARB). HIV-1 RNA was
coded as detectable or nondetectable based on the thresh-
old of the HIV-1 RNA assay utilized to allow comparison
between assays and among centers. Events such as the in-
stitution of renal replacement therapy or death and the
date of their occurrence were noted.
The kidney biopsy reports were obtained for each pa-
tient and were examined by two investigators (T.A.F.
and L.A.S.). All of the biopsies sampled renal cortex
(mean glomeruli/biopsy 21.7 ± 10.6; median 20; range
5 to 59). Eleven of the biopsies had no glomeruli avail-
able for immunofluorescence microscopy; one biopsy had
no glomeruli available for electron microscopy. Biopsies
were coded as HIVAN based on the presence of diag-
nostic features described by D’Agati et al [19]. Where
patients had features of both HIVAN and another patho-
logic process [i.e., membranous or immune complex
glomerulonephritis, not otherwise specified (NOS)], the
biopsies were coded to reflect the presence of HIVAN.
Data analysis
Creatinine clearance was calculated using the
Cockcroft-Gault formula [20]. The demographics and
laboratory parameters were described for the cohort
overall and for groups of patients defined by their
histologic diagnosis (i.e., HIVAN vs. lesions other than
HIVAN). Clinical and demographic differences between
groups were compared using the chi-square and Student
t test for categorical and continuous variables, respec-
tively. Where data were markedly skewed, the Wilcoxon
rank-sum test was used.
Renal survival distributions for groups based on his-
tologic diagnosis were estimated using the Kaplan-Meier
methodology, using initiation of renal replacement ther-
apy as the event. If the patient did not require renal re-
placement therapy, renal survival was censored at time
of last known follow-up or death. Survival distributions
were compared in univariate analysis using the log-rank
test.
The associations between clinical and demographic
variables listed in Table 1 (including academic center and
year of biopsy) and time to initiation of renal replace-
ment therapy were estimated using Cox proportional
hazards regression. The relationships between disease
progression and clinical factors such as CD4+ lymphocyte
Szczech et al: HIV-related renal disease 1147
Table 1. Patient characteristics at time of kidney biopsy
HIVAN Non-HIVAN lesions P value
Number of patients 42 13 Immune complex GN
8 Membranous nephropathy
6 Diabetic glomerulopathy
5 Membranoproliferative GN
5 Hypertensive nephrosclerosis
3 Interstitial nephritis
2 Amyloid
1 FSGS without HIVAN
1 Minimal change disease
1 Acute renal failure related to indinavir
1 IgA nephropathy
1 Chronic pyelonephritis
Gender F/M 7/35 9/38 0.76
Age yearsa 41.7 (1.42) 43.0 (1.04) 0.46
Race
White 0 2 0.02
Black 42 37
Hispanic 0 7
Native American 0 1
Risk factor
Sexual 12 11 0.22
IVDU 11 20
Hepatitis C antibody status
Positive 17 25 0.08
Negative 24 16
Hepatitis B surface antigen status
Positive 4 10 0.04
Negative 38 27
Hypertension
Present 31 24 0.03
Absent 11 23
Diabetes mellitus
Present 6 11 0.28
Absent 36 36
Systolic blood pressure mm Hga,b 133 (5) 134 (5) 0.92
Diastolic blood pressure mm Hga,b 81 (3) 81 (3) 0.94
Creatinine mg/dLa 4.7 (0.7) 2.6 (0.4) 0.006
Creatinine clearance mL/mina 39.0 (5.3) 60.6 (5.8) 0.008
Use of antiretroviral therapyb
Yes 11 16 0.42
No 31 31
Use of ACEI/ARBb
Yes 6 10 0.39
No 36 37
HIV-1 RNA levela,b 196,137 (48,513) 146,044 (46,488) 0.46
HIV-1 RNA detectable
No 5 5
Yes 37 42 0.85
CD4+ lymphocyte counta,b 187 (29) 287 (38) 0.04
Days of follow-up 457.6 (68.8) 682.4 (78.5) 0.04
Outcomes
Renal replacement therapy (RRT) 25 17 0.06
Death prior to institution of RRT 4 4
Censored at end of follow-up 13 26
Year of biopsy
1995 4 1 0.04
1996 3 4
1997 4 9
1998 8 13
1999 8 15
2000 11 5
2001 4 0
NOS, not otherwise specified; GN, glomerulonephritis.
aExpressed as mean (standard deviation).
bThese summary values represent patient information obtained at the time of biopsy. Values for laboratory parameters and use of these medications were collected
and incorporated into the analysis as they varied over the course of the disease and were added or discontinued in subsequent clinical visits and are included in the
survival analyses.
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count, HIV-1 RNA level, and the use of different classes
of medications (antiretroviral medications, ACEI, ARB,
prednisone), systolic blood pressure, and diastolic blood
pressure were examined as time-varying covariates. This
allowed the relationship between these clinical and labo-
ratory parameters and outcomes to be estimated as these
values vary over the clinical course of the HIV infection.
Creatinine clearance at time of biopsy was forced into the
model to control for differences in renal function at time
of entry into the cohort (i.e., at time of biopsy). The pro-
portional hazards assumption was tested for each of the
variables in the final model. No evidence for violation of
the proportional hazards assumption was demonstrated.
Clinically significant interactions between histologic
diagnosis (i.e., HIVAN compared with lesions other than
HIVAN) and HIV-1 RNA level, CD4+ lymphocyte count,
hepatitis C infection, and the use of antiretroviral med-
ications and ACEI or ARB on the time to initiation of
renal replacement therapy were prespecified in the design
phase of the study and tested in separate models. Where
interactions were significant, multivariable analyses were
repeated to estimate the association between those vari-
ables and outcome among patients with HIVAN and le-
sions other than HIVAN separately.
Survival models were built similarly using the com-
bined end point of initiation of dialysis or decline in
creatinine clearance to below 15 ml/min to account for
patients whose renal function declined to a level justify-
ing the initiation of renal replacement therapy [21], but
who opted against it or died prior to initiation.
The decision to compare outcomes among patients
with HIVAN to patients with all lesions other than
HIVAN was made in the design phase of this study to
address the clinical utility of renal biopsy in a popula-
tion where HIVAN is the lesion identified in significant
frequency. Following the completion of data collection,
based on the inclusion of patients with kidney disease felt
by the investigatory team to be unlikely related to HIV
infection (such as diabetes mellitus and hypertension),
additional sensitivity analyses were performed, exclud-
ing those patients to test the stability of results.
All analyses were performed using the intent-to-treat
approach (i.e., patients were analyzed according to the
treatment they were prescribed regardless of compli-
ance). All P values were reported as two-sided, and all
CIs reported were 95% intervals. All analyses were per-
formed using Stata (version 8.0, College Station, TX,
USA).
RESULTS
Eighty-nine patients were identified for inclusion.
Forty-two patients had HIVAN on renal biopsy. Those pa-
tients with lesions other than HIVAN included 13 patients
with immune complex glomerulonephritis (NOS), eight
patients with membranous glomerulopathy, six patients
with diabetic nephropathy, five patients with membra-
noproliferative glomerulonephritis, five patients with hy-
pertensive nephrosclerosis, three patients with interstitial
nephritis, two patients with amyloid, and one patient each
with FSGS without HIVAN, minimal change disease,
acute renal failure related to indinavir, IgA nephropa-
thy, and chronic pyelonephritis.
In general, patients with lesions other than HIVAN
were similar to patients with HIVAN at time of biopsy in
terms of gender, age, risk behavior for HIV acquisition,
the presence of diabetes mellitus, measures of systolic
and diastolic blood pressure, use of medications, includ-
ing antiretrovirals and ACEI/ARB, and HIV-1 RNA level
(Table 1). Patients with lesions other than HIVAN were
less likely to be black (37/47 vs. 42/42, P = 0.02), more
likely to have a positive hepatitis B surface antigen (10/37
vs. 4/42, P = 0.04), less likely to have the diagnosis of hy-
pertension (24/46 vs. 31/42, P = 0.03), more likely to have
a greater creatinine clearance at time of biopsy (60.6 vs.
39.0 mL/min, P = 0.008), and have a greater CD4 lym-
phocyte count at time of biopsy (287 vs. 187 cells/mL,
P = 0.04) compared to patients with HIVAN. Patients
with lesions other than HIVAN trended toward being
more likely to be infected with hepatitis C (25/41 vs. 17/41,
P = 0.08).
Twenty-seven patients with HIVAN and 32 patients
with lesions other than HIVAN received antiretroviral
therapy during the period of follow-up (P = 0.71). The
time to initiation of antiretroviral therapy was similar for
both groups (169 ± 249 compared with 128 ± 201 days for
patients with and without HIVAN, respectively, P = 0.49).
Creatinine clearance at time of initiation of antiretroviral
therapy was greater in patients with lesions other than
HIVAN (69 ± 41 mL/min) compared to patients with
HIVAN (41 ± 32 mL/min) (P = 0.006), there were no dif-
ferences in CD4 lymphocyte count and HIV RNA level
between groups at the time of antiretroviral initiation
(223 ± 267 vs. 249 ± 243 cells/mL, P = 0.21, and 132,429 ±
185,644 vs. 59,249 ± 108,587 copies/mL, P = 0.31 for pa-
tients with HIVAN and patients with lesions other than
HIVAN, respectively).
Seventeen of 47 patients with lesions other than
HIVAN [six with immune complex glomerulonephritis
(NOS), two with membranous nephropathy, four with
diabetic nephropathy, two with membranoproliferative
glomerulonephritis, two with hypertensive nephrosclero-
sis, and one with interstitial nephritis] required the insti-
tution of renal replacement therapy at an average time
of 731 days (± 642 days) from renal biopsy. Twenty-five
of 42 patients with HIVAN required the institution of re-
nal replacement therapy at an average time of 254 days
(±331 days) from renal biopsy (P = 0.0003 comparing
time to initiation of renal replacement therapy). There
was no difference in last available creatinine clearance
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Fig. 1. Time to initiation of renal replacement therapy from time of
renal biopsy among patients with HIV-associated nephropathy
(HIVAN) and with lesions other than HIVAN.
Table 2. Multivariable model of associations between clinical and
demographic variables and time to initiation of renal replacement
therapy among the entire cohorta
HR 95% CI P value
Lesions other than 0.33 (0.15–0.71) 0.005
HIVAN vs. HIVAN
CD4+ lymphocyte count 0.99 (0.99–0.99) 0.01
(per increase in 10 cells/mL)
Creatinine clearance 0.98 (0.97–0.99) 0.004
(at time of biopsy)
Hepatitis C Antibody 2.60 (1.26–5.37) 0.01
ACEI/ARB 0.41 (0.17–0.96) 0.04
HIV-1 RNA (nondetectable vs. 0.16 (0.02–1.18) 0.07
detectable)
aThe type of renal disease (HIVAN vs. other) interacted significantly with
HIV-1 RNA level and the use of antiretroviral therapy (P = 0.0001 and 0.006,
respectively).
prior to the institution of dialysis between groups with
and without HIVAN (13.5 ± 12.9 compared with 11.1 ±
6.0 mL/min, P = 0.78). Unadjusted survival curves
demonstrated better renal survival among patients with
lesions other than HIVAN compared to patients with
HIVAN (Fig. 1, P = 0.002).
In the fully adjusted model, lesions other than HIVAN
were associated with a longer time to initiation of renal
replacement therapy compared with HIVAN (HR 0.33,
95% CI 0.15-0.71, P = 0.005) (Table 2). Other factors as-
sociated with a longer time to renal replacement therapy
included greater CD4+ lymphocyte count (HR 0.99 per
increase in 10 cells/mL, P = 0.01) and higher creatinine
clearance at time of biopsy (HR 0.98 per 1 mL/min in-
crease, P = 0.004). The presence of hepatitis C antibody
was associated with a faster time to institution of renal
replacement therapy (HR 2.60, P = 0.01). The use of an
ACEI or ARB was associated with a longer time from
renal biopsy to institution of renal replacement therapy
(HR 0.41, P = 0.04). A nondetectable HIV-1 RNA viral
load was associated with a trend toward a longer time
from biopsy to institution of renal replacement therapy
(HR 0.16, P = 0.07).
The type of renal disease (HIVAN vs. lesions other
than HIVAN) interacted significantly with HIV-1 RNA
level and the use of antiretroviral therapy (P = 0.0001 and
0.006, respectively), indicating that the risk of progression
to the initiation of renal replacement therapy associated
with both HIV-1 RNA level and the use of antiretroviral
therapy were different among patients with HIVAN and
patients with lesions other than HIVAN. The fully ad-
justed models were estimated separately among patients
with lesions other than HIVAN and among patients with
HIVAN. Among patients with lesions other than HIVAN,
a nondetectable HIV-1 RNA was not associated with a
longer time to initiation of renal replacement therapy
(HR 0.27, 95% CI 0.03-2.4, P = 0.24). Among patients
with HIVAN, all patients had detectable virus at the time
of institution of renal replacement therapy. Because no
patient with HIVAN had nondetectable levels of HIV-1
RNA when they reached this event, this highly significant
association could not be quantified.
Among patients with lesions other than HIVAN, the
use of antiretroviral therapy was not associated with the
progression to renal replacement therapy (HR 3.29, 95%
CI 0.93-11.16, P = 0.06). Among patients with HIVAN,
the use of antiretroviral therapy was associated with a
slower progression to renal replacement therapy (HR
0.24, 95% CI 0.07-0.84, P = 0.03).
A sensitivity analysis using time to initiation of dialy-
sis as the end point, and excluding the 17 patients with
kidney disease related to diabetes mellitus, hypertension,
interstitial nephritis, FSGS (not HIVAN), acute renal fail-
ure related to indinivir, and chronic pyelonephritis also
revealed similar results in terms of direction and signif-
icance (HR 0.34 for lesions other than HIVAN as com-
pared with HIVAN, 95% CI 0.14-0.82, P = 0.02). In mod-
els excluding these patients, the type of renal disease
(HIVAN vs. lesions other than HIVAN with stated ex-
clusions) interacted significantly with HIV-1 RNA level
and the use of antiretroviral therapy (P = 0.0001 and
0.01, respectively). Among patients with lesions other
than HIVAN, the presence of nondetectable HIV-1 RNA
was not associated with a longer time to initiation of re-
nal replacement therapy (HR 0.49, 95% CI 0.05-5.05,
P = 0.55). Among patients with lesions other than
HIVAN, the use of antiretroviral therapy was not associ-
ated with the progression to renal replacement therapy
(HR 5.12, 95% CI 0.90-29.2, P = 0.07).
When initiation of dialysis or decline in renal function
below a creatinine clearance of <15 mL/min was con-
sidered as a composite end point for the entire cohort,
similar results in terms of direction and significance were
demonstrated (HR 0.41 for lesions other than HIVAN
as compared with HIVAN, 95% CI 0.20-0.85, P = 0.02).
The type of renal disease (HIVAN vs. lesions other than
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HIVAN) interacted significantly with HIV-1 RNA level
and the use of antiretroviral therapy (P = 0.0001 and
0.008, respectively). Among patients with lesions other
than HIVAN, nondetectable HIV-1 RNA was not asso-
ciated with a longer time to initiation of renal replace-
ment therapy (HR 0.30, 95% CI 0.04-2.63, P = 0.28).
Among patients with lesions other than HIVAN, the use
of antiretroviral therapy was not associated with the pro-
gression to renal replacement therapy (HR 2.25, 95% CI
0.69-7.35, P = 0.18).
Due to advanced disease, six biopsies designated as
HIVAN did not have all classic histologic features of
HIVAN well documented. In a final analysis, these biop-
sies were recoded as FSGS (non-HIVAN). There was
no change in the direction, magnitude, or significance of
these results (data not shown).
DISCUSSION
This study describes the epidemiology and clinical
course of the spectrum of HIV-related kidney diseases.
Patients with HIVAN and lesions other than HIVAN are
similar with respect to demographics and clinical char-
acteristics, with the exception of race and the presence
of hepatitis B and C infection. All patients with HIVAN
were black, while the group of patients with lesions other
than HIVAN included some white and Hispanic patients.
Additionally, patients with lesions other than HIVAN
were more likely to have concurrent infection with ei-
ther hepatitis B or C. HIVAN compared with lesions
other than HIVAN was associated with a shorter time to
the initiation of renal replacement therapy controlled for
differences in renal function at baseline. Coinfection with
hepatitis C, a decreased CD4+ lymphocyte count, and the
use of ACEI/ARB were also significantly associated with
a faster time to renal replacement therapy, while the asso-
ciation between HIV-1 RNA level and outcomes demon-
strated a trend that did not reach conventional levels of
statistical significance. Lastly, the beneficial associations
between a nondetectable HIV-1 RNA level and the use
of antiretroviral agents on the progression of renal dis-
ease seen among patients with HIVAN was not present
among patients with lesions other than HIVAN.
To our knowledge, this is the first study to document
the clinical course of a moderate number of patients with
lesions other than HIVAN exploring modifying factors.
This study is consistent with previous case reports of
patients with membranous nephropathy in which ther-
apeutic benefit was derived from medications other than
antiretrovirals (e.g., predisone) [14, 15]. Our findings
are, however, inconsistent with a smaller cohort of HIV-
infected patients with renal disease published recently
[12]. Of the 23 patients included, only 12 underwent re-
nal biopsy. While no patient who received antiretroviral
therapy experienced a doubling of serum creatinine or the
progression to ESRD, the small number of patients avail-
able for inclusion, and the limited information regarding
histology of renal lesions, limits the power and conclu-
sions that may be drawn from this study. Similarly, case
reports of a patient with membranous nephropathy and
immune-complex nephropathy demonstrate a reduction
in proteinuria [13, 22] and stable renal course [22] tem-
porally related to changes in antiretroviral regimen that
resulted in reduction in HIV-1 RNA levels. Small sample
size and limited follow-up also limit the conclusions that
may be drawn from these case reports.
Sentinel studies in both humans and animal models
provide evidence for HIVAN resulting from a direct vi-
ral infection of cells of the kidney such as the glomeru-
lar epithelial cells [23–26]. Little information is available,
however, on the pathobiology of renal diseases in the
HIV-infected patient other than HIVAN. Four HIV-
infected patients with immune-mediated proliferative
glomerulonephritis were previously examined, revealing
both circulating and in situ HIV-1 antigen-specific im-
mune complexes present in renal biopsy tissue [9]. Simi-
lar findings were present in a study of two HIV-infected
patients with IgA nephropathy [8]. While it is unclear if
lesions such as membranous glomerulopathy have similar
HIV-related immune mediation, these data suggest that
treatment focused entirely on suppressing the production
of such immune complexes through suppression of viral
replication using antiretroviral therapy may not confer
substantial benefit. Immunosuppressive therapies to af-
fect the inflammatory response to these complexes at the
level of the kidney should be tested as potential treatment
strategies, with a focus on developing treatments that may
be safely administered in this already immunosuppressed
population.
While this study presents data regarding outcomes
among patients with renal diseases other than HIVAN,
it is not without limitation. Because this study utilizes
observational data reflecting the clinical care setting,
the importance of bias introduced through the selection
of patients for biopsy, and the use of various agents,
including antiretroviral therapy and ACEI/ARB, must
be stressed. Bias may be introduced by selection for
those patients with symptoms resulting in the detection
of renal disease, referral to a nephrologist, and selec-
tion for biopsy. This bias may affect generalizability to
patients whose renal disease differs from patients pre-
sented herein with respect to characteristics at time of
biopsy. Given that limited available information on clin-
ical course has been published, clinical practice guide-
lines supporting uniform indications for biopsy are not
available. This limitation should therefore be considered
in generalizing these results to all HIV-infected patients
with kidney disease. These data may however be uti-
lized to generate hypotheses to be tested in prospective
evaluation.
Additionally, factors such as anticipated compliance
may affect the use of antiretroviral therapy and other
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therapies, such that there may be factors that affect out-
comes that result in a decision to minimize or withhold
antiretroviral use by a patients’ HIV care provider. There
were also differences between groups with respect to re-
nal function at time of biopsy. While this may reflect a
more rapid decline in renal function among patients with
HIVAN, the possibility of patients with lesions other than
HIVAN having improved access to healthcare cannot be
ruled out. These biases may impact conclusions. The im-
pact of histology on the decision to begin antiretroviral
therapy should also be considered. While there were no
differences between groups with respect to use of an-
tiretroviral therapy at biopsy or during the course of
follow-up, time to initiation of antiretroviral therapy rel-
ative to biopsy, or CD4 lymphocyte count or HIV RNA
level at time of initiation of antiretroviral therapy, it
should be noted that patients with lesions other than
HIVAN had a greater creatinine clearance at time of initi-
ation of antiretroviral therapy similar to that seen at time
of biopsy. The impact of histology on the decision to be-
gin antiretroviral therapy and, subsequently, outcomes is
not clear. However, arguably, this provides patients with
lesions other than HIVAN greater time exposure toward
having the use of antiretroviral therapy affect outcomes
if that relationship were present.
Further, patients who were lost to follow-up before
their initiation of dialysis may have introduced informa-
tive censoring in this study. While the outcomes of death
and the censoring event of end of observation are bal-
anced between groups, the potential impact of this can-
not be assessed. Because information on nephrotoxic
drugs such as nonsteroidal anti-inflammatory drugs, in-
tercurrent morbid events, and ongoing smoking or drug
abuse was not specifically collected, their impact on out-
comes cannot be assessed. Finally, while this does repre-
sent the largest cohort available for study, the limitations
of sample size must be stressed. While the associations
between both HIV-1 RNA level and antiretroviral medi-
cations demonstrated elsewhere [27–32] among patients
with HIVAN were seen in this study, the failure to find
significant associations between these variables and out-
comes among patients with lesions other than HIVAN
may represent a type II statistical error. Further exami-
nation of these relationships is essential to determine if
no such similar associations between HIV-1 RNA level
and antiretroviral medications and outcomes exist among
patients with lesions other than HIVAN, or if they are
merely attenuated as compared with the associations seen
among patients with HIVAN.
CONCLUSION
Given the survival benefit conferred by antiretrovi-
ral therapy among patients with HIV-infection, the use
of antiretroviral therapy is indicated independent of its
ability to positively affect secondary complications of
HIV infection, such as renal disease. Arguably, the non-
HIVAN renal diseases represent a spectrum of disease
with significant heterogeneity of pathobiology that is in-
completely understood. This heterogeneity may be asso-
ciated with the inconsistencies in the response of these
lesions to antiretroviral therapy. These data suggest that
antiretroviral therapy and suppression of viral replication
may not confer the same benefit to renal disease to pa-
tients with lesions other than HIVAN, as demonstrated
in observational studies among patients with HIVAN
[27, 28, 29, 32]. Given the overall mortality benefit of,
and subsequent indication for, antiretroviral therapy [33],
this may not impact the decision to begin antiretrovi-
ral therapy in the HIV-infected patient regardless of the
presence of type of renal disease. However, these data
suggest that among HIV-infected patients with renal dis-
ease other than HIVAN, the use of antiretroviral therapy
is not associated with the same beneficial effect on the
associated kidney disease. Additional therapeutic strate-
gies may need to be utilized, including immunosuppres-
sion with prednisone and other agents. For patients with
declining renal function, knowledge of their renal his-
tology would provide powerful prognostic information
that would alter therapy in the appropriate clinical cir-
cumstances. Practically, these data provide outcome in-
formation to increase the clinical utility and potentially
frequency of renal biopsy among HIV-infected patients
with renal disease.
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